Thomas Weller on Scaling Precision in Life Sciences

The company’s growth strategy centers on a pivot made in the early 2000s toward life sciences. By focusing on highly customized segments—such as inhalation systems and emerging cell and gene therapies—Weller has maintained consistent annual growth exceeding 10 percent. He argues that the future of pharmaceutical manufacturing lies in the ability to handle small, high-value batches rather than just massive, standardized production runs.

Engineering Through Partnerships

To bridge the gap between initial development and commercial production, Harro Höfliger operates as a full-solution provider. Rather than attempting to own every piece of proprietary technology, the firm utilizes a network of strategic partners, universities, and startups. This collaborative model allows the company to tackle complex engineering challenges that standard equipment providers often avoid. Weller emphasizes that the company’s internal culture prioritizes human agency over top-down management, encouraging staff to solve problems creatively as they guide clients through the entire lifecycle of a medical product.